Viking Therapeutics Stock Surges 31% As Company Advances Weight Loss Drug To Late-Stage Trial
Viking Therapeutics Stock Surges 31% As Company Advances Weight Loss Drug To Late-Stage Trial
$Viking Therapeutics (VKTX.US)$ shares are rising Thursday after the biotech company announced plans to advance its experimental weight loss drug to late-stage trials.
$Viking Therapeutics (VKTX.US)$这家生物技术公司宣布计划将其实验性减重药推进到后期试验后，股价正在上涨。
After the market close on Wednesday, Viking Therapeutics reported financial results for the second quarter that included an update on VK2735, the lead candidate of the company's unique series of novel dual agonists of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of obesity.
周三收盘后，维京治疗公司发布了第二季度的财务业绩报告，其中包括该公司一系列新型双重激动剂——Viking Therapeutics GLP-1受体和胰高糖素依赖性多肽（GIP）受体的主要候选物VK2735的最新消息，以期将其用于潜在的肥胖治疗。
Viking said earlier this year that it expected to start another mid-stage trial for VK2735, but announced late Wednesday that it would move the weekly injection into a Phase 3 trial. Viking shares popped on the news, while shares of $Eli Lilly and Co (LLY.US)$ and $Novo-Nordisk A/S (NVO.US)$ fell. Viking is one of several companies racing to capture market share in the GLP-1 market, currently being led by Lilly and Novo Nordisk.
维京公司今年早些时候表示，他们预计将为VK2735启动另一项中期试验，但周三晚间宣布将每周一次的注射转入到第3阶段的试验中。维京公司的股票因此消息上涨，而其他公司的股票则下跌。维京是几家公司之一，争取在GLP-1市场上占据市场份额，目前这一市场由Lilly和诺和诺德领导。$礼来 (LLY.US)$和页面。$诺和诺德 (NVO.US)$维京公司是几家公司之一，正在赛跑中争取在GLP-1市场占据市场份额，目前这一市场由Lilly和诺和诺德领导。
Viking said it received feedback from the U.S. Food and Drug Administration (FDA) based on a Type C meeting packet it submitted to the agency earlier this year. After reviewing the feedback, the company decided to advance VK2735 into late-stage trials for obesity.
Viking表示，它根据今年早些时候向美国食品和药物管理局（FDA）提交的C类型会议文件收到了的反馈意见。在审查这些反馈意见之后，该公司决定将VK2735引入用于肥胖的后期试验。
"The Phase 2 VENTURE study of VK2735 in obesity demonstrated up to an approximately 15% reduction in body weight from baseline following 13 weeks of dosing, as well as promising safety and tolerability. Following receipt of written feedback from an FDA Type C meeting, we are advancing this compound into Phase 3 development," said Brian Lian, CEO of Viking Therapeutics.
“VK2735在肥胖症的第二阶段创业研究中显示出从基线开始的体重下降高达15％的降幅，以及令人满意的安全性和耐受性。在接到FDA C型会议的书面反馈后，我们将把这个compound推进到第三阶段研发，”维京治疗公司CEO Brian Lian表示。
Viking expects to schedule an end-of-Phase 2 meeting with the FDA later this year. The company noted that details on the Phase 3 trial design and timing will be disclosed following the end-of-Phase 2 meeting.
Viking预计在今年晚些时候安排第二阶段结束会议。该公司指出，关于第3阶段试验的设计和时间表将在第二阶段结束会议后披露。
On the conference call late Wednesday, Lian said the company plans to test VK2735 as a monthly injection in future studies. The company also said the oral tablet version of VK2735 demonstrated encouraging signs in early trials, with up to 5.3% weight loss after 28 days. Viking expects to initiate a Phase 2 trial for the oral program later this year.
在周三的电话会议上，Lian表示，该公司计划在未来的研究中将VK2735作为每月一次的注射。该公司还表示，VK2735的口服片剂版本在早期试验中显示出令人鼓舞的迹象，28天后减重高达5.3％。 Viking预计将在今年晚些时候启动口服药项目的第2阶段试验。
Viking reported an earnings loss of 20 cents per share for the second quarter, beating analyst estimates for a loss of 27 cents per share. Analysts at HC Wainwright reiterated Buy on Thursday with a price target of $90, while Raymond James maintained a Strong Buy and lifted its target to $118.
Viking第二季度每股亏损20美分，超过了分析师预期的每股亏损27美分。HC Wainwright的分析师在周四重申买入，目标价位为90美元，而Raymond James则维持强烈买入，目标价位上调至118美元。